{"id":"W2898447893","doi":"10.1093/annonc/mdy269.181","title":"Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Palbociclib; Medicine; Breast cancer; Oncology; Tamoxifen; Internal medicine; Letrozole; Estrogen receptor; Biomarker; Gene signature; Neoadjuvant therapy; Cancer; Metastatic breast cancer; Gene expression; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002654838,0.001426788,0.001842601,0.0003231597,0.0002805507,0.001225365,0.0006535308,0.001164262,0.003345412],"category_scores_gemma":[0.001800484,0.0004652151,0.001157518,0.0003918798,0.0007020175,0.001017252,0.0004735204,0.002552897,0.0009253254],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001111708,"about_ca_system_score_gemma":0.001608348,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006597844,"about_ca_topic_score_gemma":0.001947999,"domain_scores_codex":[0.9991242,0.0005630121,0.00003183021,0.0001148943,0.0000882561,0.00007775652],"domain_scores_gemma":[0.9989715,0.0001860112,0.0002510834,0.00008486378,0.00007396418,0.0004326317],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.912262,0.01432692,0.01038328,0.0006062592,0.001324333,0.0001136753,0.00008557297,0.0008118422,0.01235245,0.0002027063,0.003420149,0.04411066],"study_design_scores_gemma":[0.7836269,0.1819338,0.02552658,0.00008980837,0.0009497926,0.0002674244,0.00006218004,0.001107893,0.001380253,0.000313286,0.004703487,0.0000387863],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837948,0.00586251,0.000310368,0.002009805,0.0003293039,0.00234591,0.001776381,0.000081283,0.00348959],"genre_scores_gemma":[0.9732462,0.00388576,0.002690733,0.003158793,0.0004390076,0.005789518,0.005687357,0.00004149475,0.005061273],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003345412,"threshold_uncertainty_score":0.01404029,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1473216235929842,"score_gpt":0.4926245432795133,"score_spread":0.345302919686529,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}